title: Lysinuric protein intolerance: reviewing concepts on a multisystem disease.
abstract: Lysinuric protein intolerance (LPI) is an inherited aminoaciduria caused by defective cationic amino acid transport at the basolateral membrane of epithelial cells in intestine and kidney. LPI is caused by mutations in the SLC7A7 gene, which encodes the y(+)LAT-1 protein, the catalytic light chain subunit of a complex belonging to the heterodimeric amino acid transporter family. LPI was initially described in Finland, but has worldwide distribution. Typically, symptoms begin after weaning with refusal of feeding, vomiting, and consequent failure to thrive. Hepatosplenomegaly, hematological anomalies, neurological involvement, including hyperammonemic coma are recurrent clinical features. Two major complications, pulmonary alveolar proteinosis and renal disease are increasingly observed in LPI patients. There is extreme variability in the clinical presentation even within individual families, frequently leading to misdiagnosis or delayed diagnosis. This condition is diagnosed by urine amino acids, showing markedly elevated excretion of lysine and other dibasic amino acids despite low plasma levels of lysine, ornithine, and arginine. The biochemical diagnosis can be uncertain, requiring confirmation by DNA testing. So far, approximately 50 different mutations have been identified in the SLC7A7 gene in a group of 142 patients from 110 independent families. No genotype-phenotype correlation could be established. Therapy requires a low protein diet, low-dose citrulline supplementation, nitrogen-scavenging compounds to prevent hyperammonemia, lysine, and carnitine supplements. Supportive therapy is available for most complications with bronchoalveolar lavage being necessary for alveolar proteinosis.
authors.affiliation: Department of Pediatrics, Federico II University, Naples, Italy. gianseb@gmail.com
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Sebastio
authors.forename: Maria P
authors.initials: MP
authors.lastname: Sperandeo
authors.forename: Generoso
authors.initials: G
authors.lastname: Andria
mesh_terms: D027241:Amino Acid Transport System y+L; D026905:Amino Acid Transport Systems / Q000235:genetics; D026923:Amino Acid Transport Systems, Basic / Q000235:genetics / Q000378:metabolism; D004847:Epithelial Cells / Q000378:metabolism; D005387:Finland; D027301:Fusion Regulatory Protein 1, Light Chains / Q000235:genetics / Q000378:metabolism; D056726:Genetic Association Studies; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D027283:Large Neutral Amino Acid-Transporter 1 / Q000235:genetics; D008239:Lysine / Q000652:urine*; D009154:Mutation; D011649:Pulmonary Alveolar Proteinosis / Q000235:genetics / Q000378:metabolism; D000608:Renal Aminoacidurias / Q000175:diagnosis / Q000178:diet therapy / Q000235:genetics* / Q000378:metabolism*
chemical_list: D027241:Amino Acid Transport System y+L; D026905:Amino Acid Transport Systems; D026923:Amino Acid Transport Systems, Basic; D027301:Fusion Regulatory Protein 1, Light Chains; D027283:Large Neutral Amino Acid-Transporter 1; C421261:SLC7A7 protein, human; D008239:Lysine